{"filing":{"accession_number":"0001140361-26-023336","cik":"0000320017","ticker":"LSTA","company_name":"LISATA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"ef20075162_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126023336/ef20075162_8k.htm"},"events":[{"id":8071,"run_id":7086,"accession_number":"0001140361-26-023336","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"This disclosure describes an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., modifying the offer price per share from $5.00 plus a $1.00 CVR to $4.00 plus a CVR with up to $3.00 in contingent payments, and extending key transaction dates. This constitutes a material modification to an ongoing material acquisition transaction, directly affecting shareholder value and deal economics.","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2639,"accession_number":"0001140361-26-023336","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure describes an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., modifying the offer price per share from $5.00 plus a $1.00 CVR to $4.00 plus a CVR with up to $3.00 in contingent payments, and extending key transaction dates. This constitutes a material modification to an ongoing material acquisition transaction, directly affecting shareholder value and deal economics.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:08:38.697802+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2639,"accession_number":"0001140361-26-023336","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"This disclosure describes an amendment to a previously announced merger agreement between Lisata Therapeutics and Kuva Labs Inc., modifying the offer price per share from $5.00 plus a $1.00 CVR to $4.00 plus a CVR with up to $3.00 in contingent payments, and extending key transaction dates. This constitutes a material modification to an ongoing material acquisition transaction, directly affecting shareholder value and deal economics.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:08:38.697802+00:00","company_name":"LISATA THERAPEUTICS, INC.","ticker":"LSTA","filing_date":"2026-05-29"}]}